Bli medlem
Bli medlem

Du är här


Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics has successfully dosed firs...

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus
Therapeutics announces today that the first cohort has been successfully
dosed in its
phase 1 study to explore the pharmacokinetics, safety and tolerability of
subcutaneous sevuparin injections in healthy adults.

Modus Therapeutic develops sevuparin for diseases with high unmet medical need
with a focus on sickle cell disease (SCD) - a painful, inherited blood
disorder affecting millions of people around the globe. Sevuparin has the
potential to improve the SCD patients' blood flow reducing their pain and the
amount of time they will need to spend in hospital.

Intravenously administered sevuparin is currently being tested in a phase 2
study which completed enrollment in January 2019 and will report data in
mid-2019. In order to broaden sevuparins potential to help SCD patients
outside of the hospital setting, Modus Therapeutics in parallel explores
subcutaneously administered sevuparin. The first cohort in a phase 1 single
ascending dose study exploring pharmacokinetics, safety and tolerability of
subcutaneous sevuparin injections in healthy volunteers has now successfully
been dosed in a U.S clinical trial facility. Subcutaneously administered
sevuparin has the potential to become a home-based, self-administered
therapeutic option for patients with SCD in the stages before and after a VOC
- the very painful crisis that are believed to contribute to the patient's
gradual accumulation of complications such as organ failure and stroke.

In November 2018 the FDA accepted Modus Therapeutics IND application. The
phase 1 study with subcutaneously administered sevuparin is the first step in
moving the clinical development of sevuparin to the United States.

"This is an important milestone for Modus Therapeutics as it both paves the
way for a new treatment option for patients with sickle cell disease and
constitutes the start of the clinical development of sevuparin in the US",
says Viktor Drvota, CEO of Karolinska Development.

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:


About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global

For more information, please

KD Press release Modus Feb 2019

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.